Mercado U

Language: Spanish
References: 6
Page: 126-127
PDF size: 28.38 Kb.

ABSTRACT

Today, we enjoy the golden age of rheumatology. In the 1970s, the paradigm for treating rheumatoid arthritis consisted in a pyramid. In the decade of the 1980s, and shortly after began a revolution in the understanding and treatment of rheumatic diseases. Methotrexate and tumor necrosis factor-blockers came on the scene.

REFERENCES

1. Wilke WS, Calabrese LH, Scherbel AL. Methotrexate in the treatment of rheumatoid arthritis: Pilot study. Cleve Clin J Med. 1980;47(4):305-9.

2. Williams HJ, Wilkens RF, Samuelson CO Jr, Alarcón GS, Guttadauria M, Yarboro C, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 1985;28(7):721-30.

3. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Effi cacy of low dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985;312(13):818-22.

4. Cronstein BN, Naime D, Ostad E. The antiinfl ammatory mechanism of methotrexate. Increased adenosine release at infl amed sites diminishes leukocyte accumulation in an in vivo model of infl ammation. J Clin Invest. 1993;92(6):2675-82.

5. Gadangi P, Longaker M, Naime D, Levin RI, Recht PA, Montesinos MC, et al. The anti-infl ammatory mechanism of sulfasalazine is related to adenosine release at infl amed sites. J Immunol. 1996;156(5): 1937-41.

6. Feldmann M, Maini RN. Anti-TNF therapy, from rationale to standard of care: What lessons has it taught us? J Immunol. 2010;185(2):791-4.